| Private Placement / Financing Transactions
Enveda Biosciences: The company raised $174 million in Series B venture funding in a deal led by Dimension. and Kinnevik on June 14, 2024, putting the company’s pre-money valuation at $226 million. Microsoft, Premji Invest , FPV Ventures, Level Ventures, Amino Collective, Possible Ventures, Air Street Capital, True Ventures, Wireframe Ventures, Lux Capital, Two Sigma Ventures, Hummingbird Ventures, Catalio Capital Management, JAZZ Venture Partners, Gaingels, Henry Kravis, Lingotto and The Nature Conservancy also participated in the round. The company is a developer of a drug discovery platform that systematically translates molecules found in medicinal plants into new drugs for challenging diseases.
Santa Ana Bio: The company raised $125 million in Series B venture funding in a deal led by GV on June 13, 2024, putting the company’s pre-money valuation at $145 million. Access Biotechnology, TPG, Versant Ventures, Andreessen Horowitz, RTW Investments and other undisclosed investors also participated in the round. The company is an operator of a biotechnology company intended to develop precision immunology for autoimmune diseases.
Bright Peak Therapeutics: The company raised $90 million of Series C venture funding in a deal led by Johnson & Johnson Innovation – JJDC on June 11, 2024. Venrock, The Invus Group, Versant Ventures, RA Capital Management, KB Investment, Alexandria Venture Investments, Northleaf Capital Partners, Fidelity Management & Research, Qatar Investment Authority and other undisclosed investors also participated in the round. The company is a developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases.
Resolute Science: The company is in the process of raising $35 million in venture funding on June 12, 2024. The company is a developer of novel therapeutics intended for aggressive, difficult-to-treat, and rare solid tumors.
Notch Therapeutics: The company raised $15.5 million in Series B venture funding from undisclosed investors on June 14, 2024. The company is a developer of a T cell-production platform.
Alida Bio: The company raised $7.5 million of Series A venture funding in a deal led by Genoa Ventures on June 12, 2024. FusionX Ventures and Vertical Venture Partners also participated in the round. The company is an operator of a biotechnology business intended to provide genomic services, reagents and software for the analysis of epigenetic markers in RNA, DNA and histones.
Neuro42: The company raised $6.6 million of venture funding from Karna D Shinde and other undisclosed investors on June 10, 2024. The company is a developer of portable magnetic resonance imaging machines designed to offer diagnosis and interventions for neurological conditions.
Immusoft: The company raised an additional $4.6 million of Series B venture funding from NYBC Ventures, RV Invest and Biovision Ventures on June 11, 2024, putting the company’s pre-money valuation at $60.7 million. Michigan Capital Network Ventures and other undisclosed investors also participated in the round. The company is a developer of novel therapies designed for the treatment of rare diseases by developing autologous cell therapies.
Cirsium Bioscences: The company raised $4.4 million of venture funding from Insight Partners, PhiFund Ventures, KdT Ventures and other undisclosed investors on June 11, 2024, putting the company’s pre-money valuation at $21.6 million. The company is an operator of a research and development biotechnology business intended for the production of gene therapies.
Checkpoint Surgical: The company raised an additional $4 million of Series C venture funding from undisclosed investors on June 13, 2024, putting the company’s pre-money valuation at $66 million. The company is a developer of surgical devices designed to locate, evaluate, and protect nerves and muscles in surgical procedures.
LightOx: The company raised $3.5 million of Series A venture funding in the form of convertible debt in a deal led by Praetura Ventures on June 12, 2024. Northstar Ventures and other undisclosed investors also participated in the round. The company is a developer of cancer therapeutics and technology designed to improve patients’ function and long-term outcomes with oral cancer.
Inanovate: The company raised $2.6 million of venture funding from undisclosed investors on June 12, 2024. The company is a developer of longitudinal assay screening technology designed for the detection and measurement of multiple proteins.
AIQ Solutions: The company raised $2.3 million of venture funding through a combination of convertible debt and equity from undisclosed investors on June 13, 2024. The company is a developer of a medical device designed to improve the evaluation of treatment response in patients with complex diseases.
1health: The company is in the process of raising venture funding on June 12, 2024. The company is an operator of an AI-powered lab network intended to provide diagnostic testing, sample collection, logistics, analytics, and monitoring services.
Genomes.io: The company received an undisclosed amount of development capital from Pantera Capital, Modular Capital and other investors on June 12, 2024. The company is a developer of a personal DNA data platform designed to provide control over genome sequencing.
Journeys Metabolic: The company is in the process of raising Series A venture funding as of June 14, 2024. The company is a developer of a metabolic digital therapeutic platform designed for targeting insulin resistance-related chronic conditions.
Leo Cancer Care: The company raised an undisclosed amount of Series C venture funding from Cone Health Ventures, EDBI and Aviko on June 11, 2024. McLaren Health, Macmillan Cancer Support and WARF Ventures also participated in the round. The company is a developer of a cancer treatment system designed to simplify radiation therapy.
Mimosa Diagnostics: The company raised an undisclosed amount of venture funding in a deal led by Kern Venture Group on June 12, 2024. Kindling Capital, Raspberry Ventures, Spring Impact Capital and other undisclosed investors also participated in the round. The company is a developer of a virtual care platform intended to visualize and assess tissue oximetry, temperature and other biomarkers without testing or wait times.
|
